{
    "clinical_study": {
        "@rank": "53474", 
        "acronym": "ITP-NODAT", 
        "arm_group": [
            {
                "arm_group_label": "Insulin treatment for hyperglycemia", 
                "arm_group_type": "Active Comparator", 
                "description": "Table 1. NPH Insulin Titration Regimen for Patients in Group A Pre-dinner Capillary blood glucose\tNPH dose initiation (IU/day)\tNPH dose adjustment(IU/day) > 240 mg/dl\t                  14\t                   Increase by 4 > 180 mg/dl\t                  12\t                   Increase by 4 > 140 mg/dl\t                  10\t                   Increase by 4 > 120 mg/dl\t                   0\t                   Increase by 2 100 to 119 mg/dl\t             0\t                   Maintain the dose 80 - <100 mg/dl\t             0\t                   Decrease by 4 60 - <80 mg/dl\t             0\t                   Decrease by 8 < 60 mg/dl\t                    0\t                  Give \u00bd of previous dose"
            }, 
            {
                "arm_group_label": "Standard of care", 
                "arm_group_type": "No Intervention", 
                "description": "Patients assigned in this arm will receive standard of care following their kidney transplantation."
            }
        ], 
        "brief_summary": {
            "textblock": "Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in\n      decreasing the incidence of NODAT among de novo kidney transplant patients with manifested\n      post-transplant hyperglycemia during the first week after transplantation.\n\n      Hypothesis 1: Early initiation of insulin therapy protects beta-cell from early stress\n      related to the surgery and use of higher doses of immunosuppressive medications, and leads\n      to lower incidence of NODAT at 1 and 2 years.\n\n      Specific Aim 2: To determine the improvement in overall glycemic control with the early\n      initiation of insulin therapy.\n\n      Hypothesis 2: Early initiation of insulin therapy results in greater overall control of\n      glycemia compared to standard care of dietary counseling, life-style modification, oral\n      hypoglycemic agents and/or insulin as needed at 1 year.\n\n      Specific Aim 3: To determine the improvement in beta-cell function among patients assigned\n      to the early initiation of insulin therapy at one year post-transplantation.\n\n      Hypothesis 3: Early initiation of insulin therapy protects beta-cell from glucotoxicity of\n      post-transplant hyperglycemia and preserves better beta-cell function at 1 year."
        }, 
        "brief_title": "A Clinical Trial to Prevent New Onset Diabetes After Transplantation", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Prevention of New Onset Diabetes Among Kidney Transplant Patients", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult patients (> 18 years) with ESRD undergoing kidney transplantation;\n\n          2. Standard triple immunosuppressive medications following kidney transplantation\n             including tacrolimus, mycophenolate moftile and corticosteroids;\n\n          3. Capable to understand the study protocol and to give informed consent;\n\n        Exclusion Criteria:\n\n        1. Type 1 and 2 DM either as co-morbidity or cause of ESRD;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01683331", 
            "org_study_id": "1R01DK092475-01"
        }, 
        "intervention": {
            "arm_group_label": "Insulin treatment for hyperglycemia", 
            "intervention_name": "Insulin treatment for hyperglycemia", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Kidney transplant", 
            "New onset diabetes", 
            "Prevention", 
            "Insulin"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": {
            "contact": {
                "email": "dcibrik@med.umich.edu", 
                "last_name": "Diane M Cibrik, MD", 
                "phone": "734-763-9031"
            }, 
            "contact_backup": {
                "email": "jlmawby@med.umich.edu", 
                "last_name": "Jennifer L Mawby, RN", 
                "phone": "734 936 4811"
            }, 
            "facility": {
                "address": {
                    "city": "Ann Arbor", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "48109"
                }, 
                "name": "University of Michigan"
            }, 
            "investigator": [
                {
                    "last_name": "Diane M Cibrik, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Akinlolu Ojo, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Fu L Luan, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Clinical Trial to Prevent New Onset Diabetes After Transplantation", 
        "other_outcome": {
            "description": "Following American Diabetes Association's definition:\nImpaired fasting glycemia: fasting glucose levels between 100 and 125 mg/dl;\nImpaired glucose tolerance: 2 hours' OGTT values between 140 and 199 mg/dl;", 
            "measure": "Incidence of impaired fasting glycemia and impaired glucose tolerance 6, 12 and 24 months after transplantation.", 
            "safety_issue": "Yes", 
            "time_frame": "6, 12 and 24 months"
        }, 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Akinlolu Ojo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "NODAT will be defined according to American Diabetes Association definition:\nFasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or\n2 hours OGTT values equal or greater than 200 mg/dl; and/or\nGlycosylated hemoglobin A1c equal or greater than 6.5; and/or\nOn oral hypoglycemic agents and/or insulin therapy;", 
            "measure": "The incidence of NODAT 12 months after kidney transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01683331"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Michigan", 
            "investigator_full_name": "Fu L Luan", 
            "investigator_title": "Clinical Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "NODAT will be defined according to American Diabetes Association definition:\nFasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or\n2 hours OGTT values equal or greater than 200 mg/dl; and/or\nGlycosylated hemoglobin A1c equal or greater than 6.5; and/or\nOn oral hypoglycemic agents and/or insulin therapy;", 
            "measure": "The incidence of NODAT 24 months after kidney transplantation", 
            "safety_issue": "Yes", 
            "time_frame": "24 months"
        }, 
        "source": "University of Michigan", 
        "sponsors": {
            "collaborator": {
                "agency": "Medical University of Vienna", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}